COMPARISON OF EFFICACY OF TOPICAL TAZAROTENE 0.1% CREAM VS ADEPALENE 0.3% AND BENZOYL PEROXIDE 2.5% IN TREATING ATROPHIC ACNE SCARS

F MUSHTAQ; MR KHAN; M SALEEM; A KHAN; S AMIN; I MUSHTAQ

doi:10.54112/bcsrj.v2024i1.1106

Authors

F MUSHTAQ Department of dermatology, PIMS Islamabad, Pakistan
MR KHAN Department of dermatology, PIMS Islamabad, Pakistan
M SALEEM Department of dermatology, PIMS Islamabad, Pakistan
A KHAN Department of dermatology, PIMS Islamabad, Pakistan
S AMIN Department of dermatology, PIMS Islamabad, Pakistan
I MUSHTAQ Department of Dermatology, CMH Multan, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1106

Keywords:

GAASS Score, Tazarotene, atrophic acne scars, Adapalene

Abstract

Atrophic acne scars are a common dermatological concern that significantly impacts patients' self-esteem and quality of life. Topical treatments such as Tazarotene and combinations of Adapalene and Benzoyl Peroxide are often used to improve the appearance of these scars. However, their comparative effectiveness requires further evaluation. Objective: To evaluate the effectiveness of Tazarotene 0.1% cream versus a combination of Adapalene 0.3% and Benzoyl Peroxide 2.5% in treating atrophic acne scars. Methods: This study was conducted in the Dermatology Department of PIMS, Islamabad, from January to June 2024, following approval from the hospital’s ethical committee. A total of 140 participants with atrophic acne scars were enrolled and divided into two groups. Group A received Tazarotene 0.1% cream, while Group B was treated with a combination of Adapalene 0.3% and Benzoyl Peroxide 2.5%, both applied once daily at night. The treatment duration was 12 weeks. The severity of acne scars was assessed using the Global Atrophic Acne Scar Scale (GAASS), and the impact on quality of life was measured using the Quality-of-Life Score. Statistical analysis was performed using SPSS Version 26, with significance set at p < 0.05. Results: The mean age of participants was 40.40 ± 11.24 years. Before treatment, GAASS scores were comparable between Group A (3.70 ± 0.64) and Group B (3.80 ± 0.65, p = 0.36). After 12 weeks, Group A showed significantly greater improvement, with a mean GAASS score of 1.72 ± 0.63 compared to 2.17 ± 0.77 in Group B (p = 0.00). Patient satisfaction was also higher in Group A (7.4 ± 1.5) compared to Group B (6.8 ± 1.7, p = 0.00). The Quality-of-Life Score was slightly higher in Group A (85.3 ± 5.2) than in Group B (82.7 ± 6.1), although this difference was not statistically significant (p = 0.14). Side effects were reported in 17.1% of Group A and 27.1% of Group B (p = 0.15). Conclusion: Tazarotene 0.1% cream was more effective than the combination of Adapalene 0.3% and Benzoyl Peroxide 2.5% in treating atrophic acne scars. Despite no significant difference in quality-of-life improvements between the two treatments, tazarotene patients experienced more significant scar reduction, higher satisfaction, and fewer side effects.

Downloads

Download data is not yet available.

References

Ak M. A comprehensive review of acne vulgaris. J Clin Pharm. 2019;1(1):17-45.

Brown B, McKenna S, Siddhi K, McGrouther D, Bayat A. The hidden cost of skin scars: quality of life after skin scarring. Journal of Plastic, Reconstructive & Aesthetic Surgery. 2008;61(9):1049-58.

Nandy P, Shrivastava T. Exploring the multifaceted impact of acne on quality of life and well-being. Cureus. 2024;16(1).

Leung AK, Barankin B, Lam JM, Leong KF, Hon KL. Dermatology: how to manage acne vulgaris. Drugs in context. 2021;10.

Afra T, Razmi M, Narang T, Dogra S, Kumar A. Topical tazarotene gel, 0.1%, as a novel treatment approach for atrophic postacne scars: a randomized active-controlled clinical trial. JAMA facial plastic surgery. 2019;21(2):125-32.

Ghodsi SZ, Orawa H, Zouboulis CC. Prevalence, severity, and severity risk factors of acne in high school pupils: a community-based study. Journal of investigative Dermatology. 2009;129(9):2136-41.

Nouri K, Ballard CJ. Laser therapy for acne. Clinics in dermatology. 2006;24(1):26-32.

Nurjanti L. The Role of Immunological Reaction and Pro Inflammatory Mediators in Acne Vulgaris Etiopathogenesis, Applications in Dermatology Practice. International Journal of Clinical & Experimental Dermatology. 2019;4(1):1-44.

Fife D. Practical evaluation and management of atrophic acne scars: tips for the general dermatologist. The Journal of clinical and aesthetic dermatology. 2011;4(8):50.

Gozali MV, Zhou B. Effective treatments of atrophic acne scars. The Journal of clinical and aesthetic dermatology. 2015;8(5):33.

Galindo SK, Spillman TL, Zuckerman DM. The Pathophysiology and Etiology of Acne Vulgaris and the Pharmacology of Treatments. Bios. 2024;95(1):52-8.

Fabbrocini G, Annunziata MC, D′ Arco V, De Vita V, Lodi G, Mauriello M, et al. Acne scars: pathogenesis, classification and treatment. Dermatology research and practice. 2010;2010(1):893080.

Goodman GJ. Management of post-acne scarring: what are the options for treatment? American journal of clinical dermatology. 2000;1:3-17.

Swathi D, Aithal S. A Study of Psychological Impact of Acne Vulgaris on Quality of Life Using CADI & DLQI Scoring in Patients Attending Dermatology OPD in Tertiary Care Hospital: Rajiv Gandhi University of Health Sciences (India); 2018.

Waibel JS, Waibel H, Sedaghat E. Scar Therapy of Skin. Facial Plastic Surgery Clinics of North America. 2023;31(4):453-62.

Fisher GJ, Datta S, Wang Z, Li X-Y, Quan T, Chung JH, et al. c-Jun–dependent inhibition of cutaneous procollagen transcription following ultraviolet irradiation is reversed by all-trans retinoic acid. The Journal of Clinical Investigation. 2000;106(5):663-70.

Dreno B, Tan J, Rivier M, Martel P, Bissonnette R. Adapalene 0.1%/benzoyl peroxide 2.5% gel reduces the risk of atrophic scar formation in moderate inflammatory acne: a split‐face randomized controlled trial. Journal of the European Academy of Dermatology and Venereology. 2017;31(4):737-42.

Loss MJ, Leung S, Chien A, Kerrouche N, Fischer AH, Kang S. Adapalene 0.3% gel shows efficacy for the treatment of atrophic acne scars. Dermatology and therapy. 2018;8:245-57.

Kubba R, Layton A, Miyachi Y, Perez M, Martin JP, Ramos-e-Silva M, et al. New insights into the management of acne: An update from the Global Alliance to Improve Outcomes in Acne Group.